FDA Path Clears, Manufacturing Ramps Up + $22.3 Million Strengthens the Balance Sheet; Inflection Point for NRx Pharmaceuticals (N A S D A Q: NRXP)

MIAMI - Rezul -- For NRx Pharmaceuticals (N A S D A Q: NRXP) $NRXP, August 17, 2026 could prove to be one of the more important dates in the company's recent history.

Today, NRx reported its second-quarter 2026 financial results and provided a sweeping corporate update that goes well beyond the numbers. The company is increasingly positioning itself for a transition from a development-stage biotechnology company toward a commercial pharmaceutical and neuropsychiatric platform.

The centerpiece remains the FDA pathway for NRx's preservative-free intravenous ketamine.

But today's announcement adds an important new dimension: NRx says it has already submitted the sole remaining manufacturer attestation requested by the FDA, is building five million doses of launch inventory, expects existing cash to fund at least one year of operations, and has secured a potential DARPA-funded opportunity exceeding $11.5 million.

That combination makes today's update particularly interesting for investors.

The FDA Story Has Become Much More Focused

The FDA completed its first-cycle review of NRx's ANDA for preservative-free ketamine without identifying major deficiencies involving the drug product, ingredients, proposed labeling, Chemistry, Manufacturing and Controls, or other drug-related matters.

The remaining issue concerns the luer-lock component of the vial—the portion connecting the vial to a syringe.

NRx says the FDA requested an attestation confirming that the vial is manufactured in the same manner as the vial used for three already-approved drugs that collectively ship more than 11.9 million units annually. The company has now submitted that attestation and is targeting approval and commercialization in 2026.

This distinction is critical.

Investors should not confuse the remaining FDA item with a request for additional clinical trials or new efficacy or safety data. According to NRx, no new clinical, safety or efficacy data are required for ANDA approval.

That substantially changes the character of the regulatory story.

Instead of waiting for another major clinical development program, investors are watching for resolution of a specific packaging/manufacturing certification.

NRx Is Already Preparing for Commercialization

Perhaps the most important operational development in today's release is that NRx isn't waiting for final approval to begin preparing its supply chain.

The company has initiated commercial-scale manufacturing of preservative-free ketamine and is currently building approximately 5 million doses of launch inventory, with anticipated post-launch production of approximately 1 million doses per month.

That gives investors a much clearer picture of management's strategy.

If FDA approval arrives as anticipated, NRx intends to have product available rather than beginning manufacturing from scratch.

Key commercialization indicators now include:

• FDA first-cycle review substantially completed
• Remaining manufacturer attestation submitted
• Five million doses of launch inventory being manufactured
• Planned production capacity of approximately one million doses per month after launch
• Commercial launch team already retained
• Glenn Tyson appointed as NRx's first Chief Commercial Officer

The company is therefore building the infrastructure required for a potential transition into commercial operations.

More on Rezul News

• Fall 2026 Forecast for the Real Estate Market
• Fountain Hills, AZ Single-Family Activity Strengthens as Sales Above $1.5 Million Rise 57.9%
• BlazeHive's AI SEO Agent Outranks Human Writers on 500+ Google Top-3 Results in 5 Months, on Autopilot
• ConnectNeighbors.com changes model - Realtors are now free of charge
• Priority Property Group Becomes Preferred Property Management Partner for Charlotte Investors

Today's Financial Update Adds Another Layer to the Story

NRx also reported a significantly stronger balance sheet.

As of June 30, 2026, the company had approximately $26.7 million in cash and cash equivalents, compared with $7.8 million at the end of 2025. NRx raised gross proceeds of approximately $22.3 million through an institutionally supported, underwritten public offering, including the full exercise of the underwriters' option.

The company reported a six-month net loss of approximately $18.0 million, compared with $23.1 million in the comparable period of 2025.

For investors, the important point isn't simply the quarterly loss.

It is the combination of cash, manufacturing preparation, potential near-term commercialization and growing clinic revenue.

Management believes existing resources, anticipated clinic revenue and potential use of its active ATM facility can support operations for at least one year.

That gives NRx additional runway to pursue its regulatory and commercial objectives.

DARPA Could Add a Major Non-Dilutive Catalyst

NRX-101 may be the company's other major opportunity.

NRx announced that its subsidiary was selected by the Defense Advanced Research Projects Agency (DARPA) as prime contractor for the SPARC-TMS program, an FDA-approved Phase 2/3 study combining NRX-101 with robotic-assisted TMS.

The anticipated non-dilutive funding is expected to exceed $11.5 million, subject to completion of contracting.

The program is designed to evaluate whether NRX-101—NRx's D-cycloserine/lurasidone combination—can enhance robotic TMS treatment for depression.

The planned research involves Harvard McLean Hospital, HOPE Therapeutics clinics and designated military treatment facilities, including Walter Reed National Military Medical Center.

That creates a potentially powerful second pathway for investors.

NRx isn't relying entirely on ketamine.

NRX-100 Creates Another Potential FDA Catalyst

The company is also advancing its NRX-100 NDA for preservative-free ketamine as a treatment for depression.

Today's release says NRx is leveraging real-world evidence involving more than 65,000 patients, following a Presidential Executive Order and Congressional budget language encouraging FDA consideration of real-world evidence in depression treatments. The company is now targeting a 2027 approval for this NDA pathway.

That is strategically important because NRx is pursuing two distinct opportunities around essentially the same underlying ketamine platform:

ANDA: Potential near-term entry into the existing generic ketamine market.

NDA: A differentiated regulatory pathway targeting ketamine for depression and potentially broader clinical applications.

Success in the ANDA pathway could therefore become a commercial foundation while the NDA program continues developing.

HOPE Therapeutics Continues Building the Commercial Platform

NRx's HOPE Therapeutics subsidiary is also expanding.

The company added sites in Sarasota and Boca Raton, Florida, and became the first commercial site in the United States to treat patients using Zeta Surgical's FDA-cleared TMS navigation system.

This matters because HOPE provides NRx with an operating clinical platform rather than simply a pipeline of laboratory assets.

More on Rezul News

• On the Boards: Proform Builds Announce New Construction in Alki, Seattle
• On the Boards: Proform Builds Announce New Construction in Gig Harbor
• Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism
• Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
• Dana Flanagan Expands the Authority Architect, Bringing a Nontraditional Approach to Executive Authority, Strategic Access and Business Growth

The company has already begun generating clinical revenue, while the network is being expanded around interventional psychiatry and technologies such as TMS.

That could eventually give NRx multiple revenue-generating components:

• Pharmaceutical products
• Clinical treatment centers
• Neuropsychiatric technologies
• Potential government-funded programs
• Licensing and intellectual property opportunities

The Investor Watchlist Is Getting Longer

With today's update, several catalysts now sit in front of NRXP investors:

• FDA resolution of the remaining ketamine packaging certification
• Potential 2026 approval of preservative-free ketamine
• Commercial launch and initial sales
• Five million-dose launch inventory
• Production ramp toward one million doses monthly
• Completion of DARPA contracting and potential $11.5M+ non-dilutive funding
• Progress toward the NRX-100 NDA
• Continued HOPE Therapeutics clinic expansion
• Advancement of NRX-101 with robotic TMS

That is a considerably different risk/reward profile from a company waiting for a single clinical trial result.

Investor Perspective: NRXP May Be Approaching a Defining Moment

There are still substantial risks. FDA approval is not guaranteed, commercial execution must be demonstrated, the company continues to incur operating losses, and additional capital could ultimately be required.

Nevertheless, today's announcement materially strengthens the argument that NRx is approaching an important inflection point.

The preservative-free ketamine program has moved beyond a purely developmental story. NRx has completed the FDA's first-cycle review without drug-related major deficiencies, submitted the remaining manufacturer attestation, begun building millions of doses of launch inventory and assembled a commercial team. At the same time, the company has strengthened its balance sheet with $22.3 million of gross financing proceeds and believes it has at least a year of operating runway.

And then there is NRX-101.

The potential DARPA-backed SPARC-TMS program could provide more than $11.5 million of non-dilutive funding while simultaneously advancing a potentially differentiated neuropsychiatric treatment strategy.

For investors, that is what makes NRXP particularly intriguing at this stage.

The company's story is no longer simply about whether NRx can develop a drug.

It is increasingly about whether NRx can convert regulatory progress into commercial revenue while simultaneously building a broader neuropsychiatric platform around ketamine, NRX-101, TMS and HOPE Therapeutics.

If the FDA completes the remaining packaging review and preservative-free ketamine receives approval, the company could move rapidly from preparation to commercialization—with millions of doses already being manufactured.

That potential transition from "development story" to "commercial launch story" is arguably the most important catalyst now sitting in front of NRXP.

For more information on $NRXP visit: https://www.nrxpharma.com/ and https://compasslivemedia.com/case-study/nrx-pharmaceuticals/

Company Contact
NRx Pharmaceuticals, Inc. (N A S D A Q: NRXP)
Matthew Duffy – Chief Business Officer
Phone: (484) 254-6134
Email: mduffy@nrxpharma.com

DISCLAIMER: https://corporateads.com/disclaimer/
Disclosure listed on the CorporateAds website